LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
MGTX
MeiraGTx Holdings plc
There isn't enough reported data to score MGTX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MGTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Under pressure | |
| Strong |
MGTX's profitability and balance sheet are currently strong, but its cash flow is under pressure. There isn't enough data to rate its revenue.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MGTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 11x | $8.79 | — |
| Cheap | 13x | $10.39 | +18% |
| Fair | 15x | $12.22 | +39% |
| Expensive | 19x | $15.50 | +76% |
Historical ranges are pointers, not guarantees.
MGTX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MGTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect MGTX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MGTX on earnings, with more consistent year-over-year improvement.
MGTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.80 | +$2.90 |
| Q2 2026 | $0.71 | +$2.74 |
| Q1 2026 | -$1.48 | +$0.83 |
| Q4 2025 | -$1.42 | +$0.70 |
| Q3 2025 | -$2.10 | -$0.87 |
| Q2 2025 | -$2.03 | -$0.61 |
| Q1 2025 | -$2.31 | -$1.12 |
| Q4 2024 | -$2.12 | -$0.63 |
MGTX has returned to profit: it earned $0.80 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MGTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MGTX on profitability, with a higher operating margin.
MGTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.8M | +1074% |
| Q2 2026 | $321.4M | +8609% |
| Q4 2025 | $75.4M | +252% |
| Q3 2025 | $410K | -96% |
| Q2 2025 | $3.7M | +1209% |
| Q3 2024 | $10.9M | +114% |
| Q2 2024 | $282K | -92% |
| Q1 2024 | $697K | -79% |
MGTX's revenue is growing: $5M last quarter, up 1074% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1036% | +10196 points |
| Q2 2026 | 76% | +1290 points |
| Q1 2026 | -13931% | N/A |
| Q4 2025 | 35% | +182 points |
| Q3 2025 | -11232% | -10865 points |
| Q2 2025 | -1214% | +15066 points |
| Q4 2024 | -147% | N/A |
| Q3 2024 | -367% | +275 points |
MGTX's operating margin was −1036% last quarter, up 10196 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MGTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
MGTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.3M | -$13.5M |
| Q2 2026 | -$38.9M | +$6.3M |
| Q1 2026 | $15.8M | +$54.3M |
| Q4 2025 | $46.4M | +$70.9M |
| Q3 2025 | -$12.8M | +$12.9M |
| Q2 2025 | -$45.2M | -$24.4M |
| Q1 2025 | -$38.5M | -$119K |
| Q4 2024 | -$24.5M | -$6.9M |
MGTX has burned cash in almost every quarter: −$3M over the past year, against −$121M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MGTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MGTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +3.1M shares |
| 1 year | +20% | +15.9M shares |
| 3 years | +63% | +37.4M shares |
| 5 years | +119% | +52.7M shares |
| Available history | +192% | +63.7M shares |
MGTX has 97M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $18.2M |
| Q4 2022 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MGTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
MGTX has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MGTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.5 | Neutral |
| Stochastic | 6.8 | Oversold |
MGTX's weekly RSI is 38 (neutral) and its Stochastic is 7 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MGTX PE vs Healthcare Sector
| Metric | MGTX | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 57% below |
MGTX has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MGTX on trend strength, trading above more of its moving averages.
MGTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.77 | 10% below |
| 20 week MA | $11.8 | 26% below |
| 50 week MA | $9.90 | 11% below |
| 100 week MA | $8.49 | 3.5% above |
| 200 week MA | $7.11 | 24% above |
MGTX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 24% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MGTX on returns for 2026, with the stronger performance.
MGTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.1 | $16.4 | -18% |
| 2021 | $16.4 | $22.4 | +36% |
| 2022 | $22.4 | $6.01 | -73% |
| 2023 | $6.01 | $7.02 | +17% |
| 2024 | $7.02 | $6.21 | -12% |
| 2025 | $6.21 | $7.97 | +28% |
| 2026 YTD | $7.97 | $8.79 | +10% |
MGTX has finished lower in three of the last six years. It's up 10% so far in 2026.